Beyond Monotherapy: Targeting the Triad of Insulin Resistance, Hyperandrogenism and Obesity in Polycystic Ovary Syndrome
Abstract
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting women of reproductive age group. It is a heterogeneous condition with multifactorial etiology and polygenic inheritance. Most prevalent current management of PCOS involves oral contraceptive pills (OCPs) with/without antiandrogens along with lifestyle modification. Given the multifaceted pathophysiology of PCOS, addressing it with a single pharmacologic agent makes long-term management difficult. The comprehensive management of PCOS must target the clinical symptomatology as well as underlying pathophysiologic mechanisms. Obesity, which is commonly observed in PCOS, contributes significantly in the pathophysiology of PCOS by exacerbating insulin resistance (IR) and hyperandrogenism. Women with Obesity and PCOS have poorer metabolic and reproductive outcomes than nonobese women. Although OCPs are widely used as first-line pharmacologic agents, they may worsen metabolic function and have multiple adverse effects and contraindications. Metabolic dysfunction is more prevalent in women with obesity and PCOS due to the additive effect of obesity and PCOS. Hence, there is an urgent need of a multipronged approach that targets both the pathophysiology and symptomatology in women with obesity and PCOS. Although combination therapies for management of PCOS have been explored in the past, an integrated approach addressing all 3 components of obese PCOS together-namely IR, hyperandrogenism, and obesity…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.